Nevro Debt to Equity Ratio 2013-2022 | NVRO

Current and historical debt to equity ratio values for Nevro (NVRO) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Nevro debt/equity for the three months ending September 30, 2022 was 0.57.
Nevro Debt/Equity Ratio Historical Data
Date Long Term Debt Shareholder's Equity Debt to Equity Ratio
2022-09-30 $0.28B $0.33B 0.86
2022-06-30 $0.29B $0.23B 1.28
2022-03-31 $0.29B $0.24B 1.22
2021-12-31 $0.27B $0.30B 0.89
2021-09-30 $0.26B $0.32B 0.83
2021-06-30 $0.24B $0.36B 0.67
2021-03-31 $0.41B $0.37B 1.12
2020-12-31 $0.40B $0.39B 1.03
2020-09-30 $0.40B $0.38B 1.05
2020-06-30 $0.38B $0.37B 1.01
2020-03-31 $0.25B $0.22B 1.14
2019-12-31 $0.25B $0.22B 1.17
2019-09-30 $0.25B $0.20B 1.26
2019-06-30 $0.25B $0.20B 1.22
2019-03-31 $0.24B $0.21B 1.14
2018-12-31 $0.22B $0.25B 0.89
2018-09-30 $0.21B $0.24B 0.85
2018-06-30 $0.20B $0.25B 0.83
2018-03-31 $0.20B $0.24B 0.83
2017-12-31 $0.21B $0.25B 0.82
2017-09-30 $0.19B $0.24B 0.79
2017-06-30 $0.18B $0.24B 0.75
2017-03-31 $0.18B $0.24B 0.72
2016-12-31 $0.18B $0.25B 0.73
2016-09-30 $0.17B $0.25B 0.70
2016-06-30 $0.17B $0.25B 0.67
2016-03-31 $0.05B $0.23B 0.20
2015-12-31 $0.06B $0.24B 0.24
2015-09-30 $0.04B $0.24B 0.18
2015-06-30 $0.04B $0.26B 0.14
2015-03-31 $0.03B $0.16B 0.21
2014-12-31 $0.03B $0.17B 0.18
2014-09-30 $0.01B $0.05B 0.19
2014-06-30 $0.00B $0.00B 0.00
2014-03-31 $0.00B $0.00B 0.00
2013-12-31 $0.00B 0.00
2013-09-30 $0.00B $0.00B 0.00
2012-12-31 $0.01B $0.04B 0.13
Sector Industry Market Cap Revenue
Medical Medical Instruments Manufacturing $1.601B $0.387B
Nevro Corp. is a medical device company which engages in developing and commercializing a neuromodulation platform for the treatment of chronic pain, primarily in the leg. The company is known for developing and commercializing the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. Additionally, the company's HF10 therapy provides long-lasting relief from chronic back and leg pain. Nevro's flagship Senza SCS system has been consistently driving the top line. Since its commercial launch in the United States, the system raked in significant revenues. These apart, Senza is commercially available in Europe since 2010 and in Australia since 2011.
Stock Name Country Market Cap PE Ratio
Thermo Fisher Scientific (TMO) United States $220.806B 23.09
Edwards Lifesciences (EW) United States $47.328B 32.57
Alcon (ALC) Switzerland $34.365B 29.59
STERIS (STE) Ireland $19.157B 23.84
Teleflex (TFX) United States $11.379B 18.46
Fresenius Medical Care AG KGaA (FMS) Germany $9.600B 9.64
Penumbra (PEN) United States $8.008B 1916.82
Globus Medical (GMED) United States $7.483B 38.05
Integer Holdings (ITGR) United States $2.426B 19.47
Glaukos (GKOS) United States $2.281B 0.00
Paragon 28 (FNA) United States $1.511B 0.00
AVANOS MEDICAL, INC (AVNS) United States $1.261B 17.96
Artivion (AORT) United States $0.546B 0.00